Stockholm, Sweden

Updated regulatory plans for NEFECON

Calliditas Therapeutics AB (Nasdaq:

CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that partner Everest Medicines (HKEX 1952.HK) plans to submit

an NDA for NEFECON in China in the second half of 2022.

Everest received Breakthrough Therapy

Designation (BTD) from the China Center for Drug Evaluation, National Medical Products Administration (CDE,NMPA) in December, 2020 and

have completed enrollment of the 60 Chinese patients required to complement the submission of the global data set from the NefIgArd trial.

Everest plans to conduct an interim analysis of the Chinese patients and this is expected to lead to a regulatory submission in China

"We are excited about the possibility

of a significantly earlier potential approval in China, and are happy to support our partner Everest in their endeavors to bring the

first approved medicine for IgA nephropathy to Chinese patients," said CEO Ren e Aguiar-Lucander.

As previously reported, in 2019 Calliditas

entered into a license agreement to develop and commercialize NEFECON in Greater China and Singapore for the chronic autoimmune kidney

disease IgA Nephropathy (IgAN). In March 2022, Calliditas expanded this partnership to include South Korea.

For further information, please contact:

Marie Galay, IR Manager, Calliditas

Tel.: +44 79 55 12 98 45, email: marie.galay@calliditas.com

The information was sent for publication,

through the agency of the contact persons set out above, on March 18, 2022 at 8:00 a.m. CET.

Calliditas Therapeutics

is a commercial stage biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments

in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead

product, TARPEYOTM (budesonide) delayed release capsules has been approved by the FDA and is the subject of a marketing authorization

application (MAA) with the European Medicines Agency (EMA). Additionally, Calliditas is conducting a pivotal clinical trial with its

NOX inhibitor product candidate setanaxib in primary biliary cholangitis and is initiating a head and neck cancer Phase 2 trial with

setanaxib. Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed

on the Nasdaq Global Select Market (ticker: CALT).

Forward-Looking Statements

This press release contains

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including,

without limitation, statements regarding Calliditas' strategy, commercialization efforts, business plans, regulatory

submissions, clinical development plans and focus. The words "may," "will," "could,"

"would," "should," "expect," "plan," "anticipate," "intend,"

"believe," "estimate," "predict," "project," "potential,"

"continue," "target," and similar expressions are intended to identify forward-looking statements, although

not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based

on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors

that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements

contained in this press release, including, without limitation, any related to Calliditas' business, operations, continued FDA

approval for TARPEYO, market acceptance of TARPEYO, clinical trials, supply chain, strategy, goals and anticipated timelines,

competition from other biopharmaceutical companies, and other risks identified in the section entitled "Risk Factors" in

Calliditas' reports filed with the Securities and Exchange Commission. Calliditas cautions you not to place undue reliance on

any forward-looking statements, which speak only as of the date they are made. Calliditas disclaims any obligation to publicly

update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any

such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the

forward-looking statements. Any forward-looking statements contained in this press release represent Calliditas' views only as

of the date hereof and should not be relied upon as representing its views as of any subsequent date.